Physician profile
Lan Tran
NPI 1235620675
$1,523.13
in general payments reported to CMS, 2019-2025
34 companies · $1,064 in 2025
The $1,064 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $459 · 2025: $1,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,433.14 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $178.68 | 2024-2025 | Reblozyl, Opdualag |
| Incyte Corporation | $153.04 | 2024-2025 | Monjuvi, Zynyz, Pemazyre |
| Pfizer INC. | $128.95 | 2024-2025 | |
| Abbvie INC. | $88.64 | 2024-2025 | |
| Eisai INC. | $78.03 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $74.59 | 2025 | |
| Daiichi Sankyo INC. | $69.59 | 2025 | Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $67.27 | 2025 | Opdivo |
| Janssen Biotech, INC. | $50.67 | 2024-2025 | Darzalex, Akeega, Balversa |
| Karyopharm Therapeutics INC. | $45.89 | 2024-2025 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $42.95 | 2024-2025 | Alunbrig, Ninlaro |
| Merck Sharp & Dohme LLC | $42.68 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Astrazeneca Pharmaceuticals LP | $34.10 | 2025 | |
| Glaxosmithkline, LLC. | $32.51 | 2024-2025 | Blenrep, Ojjaara |
| Janssen Scientific Affairs, LLC | $31.52 | 2025 | Talvey, Tecvayli, Darzalex |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iovance Biotherapeutics, INC. | $29.16 | 2025 | Amtagvi |
| Syndax Pharmaceuticals, INC. | $27.85 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.13 | 2024 | Gilotrif |
| Amgen INC. | $24.00 | 2025 | Imdelltra (Amg757) |
| Alexion Pharmaceuticals, INC. | $23.74 | 2024 | Ultomiris |
| Geron Corporation | $22.50 | 2025 | Rytelo |
| Aveo Pharmaceuticals, INC. | $22.38 | 2025 | |
| Genmab U.S., INC. | $22.20 | 2025 | Epkinly |
| Adaptive Biotechnologies Corporation | $21.74 | 2024 | Clonoseq |
| Adc Therapeutics America, INC. | $20.94 | 2025 | |
| Beigene USA, INC. | $20.67 | 2024 | Brukinsa |
| Sobi, INC | $20.55 | 2025 | |
| Celltrion USA INC. | $20.05 | 2024 | Vegzelma |
| Genentech USA, INC. | $19.48 | 2024 | Venclexta |
| Lilly USA, LLC | $18.62 | 2024 | Verzenio, Jaypirca, Retevmo |
| Kyowa Kirin, INC. | $17.47 | 2025 | |
| Jazz Pharmaceuticals INC. | $16.71 | 2025 | |
| Springworks Therapeutics, INC. | $15.31 | 2025 | Ogsiveo |
| Array Biopharma INC | $13.52 | 2025 | Tukysa, Braftovi, Mektovi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lan Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.